{"schema_version":"secwatch.filing_event.v1","accession":"0001437749-24-017059","form_type":"8-K","ticker":null,"cik":"0001029125","company_name":"Panbela Therapeutics, Inc.","filed_at":"2024-05-15T23:59:59+00:00","discovered_at":"2026-05-14T18:03:16.940676+00:00","generated_at":"2026-06-01T22:29:27.493209+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Panbela Q1 net loss $7.1M; ASPIRE trial interim analysis delayed to Q1 2025 due to lower event rate","bullets":["ASPIRE trial interim OS analysis delayed to Q1 2025; lower-than-expected event rate may signal improved survival.","ASPIRE enrollment >50%; complete enrollment of ~600 patients expected by Q1 2025.","Q1 2024 R&D expenses $5.5M (up from $3.5M YoY) driven by ASPIRE expansion; net loss per share $2.28.","Cash $262k as of March 31; closed $9.0M public offering in January; $0.8M nondilutive payment from US WorldMeds in April.","Stock moved to OTCQB; new US and Canada patent for eflornithine/sulindac fixed dose combination."],"urls":{"canonical":"https://secwatch.observer/filing/0001437749-24-017059","json":"https://secwatch.observer/filing/0001437749-24-017059.json","markdown":"https://secwatch.observer/filing/0001437749-24-017059.md","text":"https://secwatch.observer/filing/0001437749-24-017059.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1029125/000143774924017059/0001437749-24-017059-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1029125/000143774924017059/pbla20240514_8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-01T22:29:27.493209+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"cf87d7dc36d394357d1ee52b188bc9f07649ad12","claim":"Panbela Therapeutics, Inc. reported the quarter ended March 31, 2024 results: net income Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share, EPS $2.28 per diluted share.","evidence_excerpt":"Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share, compared to a net loss of $5.1 million, or $392.76 per diluted share, in the same period last year.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1029125/000143774924017059/0001437749-24-017059-index.htm","confidence":0.95,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the quarter ended March 31, 2024"},{"label":"Net income","value":"Net loss in the quarter was approximately $7.1 million, or $2.28 per diluted share"},{"label":"EPS","value":"$2.28 per diluted share"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}